338453-29-5

Usage

Uses

Used in Pharmaceutical Industry:
Tetrahydro-2-Furanmethanesulfonyl chloride is used as a synthetic reagent for the development of pharmaceutical agents, specifically targeting the treatment of HBV (Hepatitis B Virus) infection. Its role in the synthesis process aids in creating effective treatments to combat this viral infection.

Upstream product

• 3003-84-7 Tetrahydrofurfuryl chloride 
• 1192-30-9 tetrahydrofurfuryl bromide 
• 1062292-82-3 C₆H₁₂N₂OS*ClH 
• 14605-21-1 bis-tetrahydrofurfuryl disulfide 

Downstream Products

• 1062292-04-9 C₂₅H₂₄N₄O₄S 
• 338457-63-9 tetrahydrofuran-2-yl-methanesulphonic acid 5-(2,4-diamino-pyrimidin-5-ylmethyl)-3-ethoxy-2-iodo-phenyl ester 

Relevant academic research and scientific papers

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compound and composition thereof, and uses of substituted heteroaryl compound and composition thereof

The present invention provides a substituted heteroaryl compound and a composition thereof, and uses of the substituted heteroaryl compound and the composition, wherein the compound is a compound represented by a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound represented by the formula (I). The present invention further provides a pharmaceutical composition containing the compound, wherein the pharmaceutical composition can regulate activity of protein kinases, particularly Aurora kinases and JAK kinases, and can be used for prevention, treatment, therapy and alleviation of protein kinases, particularly Aurora kinases and JAK kinase activity mediated diseases or disorders.

PHTHALAZINONE DERIVATIVES

A compound of the formula (I) wherein: A and B together represent an optionally substituted, fused aromatic ring or an optionally substituted, fused cyclohexene ring; D is selected from: (i), where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N and Y4 is selected from CH and N; (ii) where Y1is selected from CH and N and Y2 is selected from CH and N; (iii) and where Q is O or S; and (iv), where Q is O or S; and RD is an optionally substituted C5-20 aryl group, bound to D by a carbon-carbon bond.

Substituted 5-benzyl-2,4-diaminopyrimidines

The invention relates to substituted 5-benzyl-2,4-diaminopyrimidines of general formula (A) wherein R1is C2-C3 alkyl an R2is heterocyclyl, phenyl or naphthyl, bonded by one of its C-atoms and R3is C2-C6 alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, alkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfamoyl, heterocyclysylfonyl, heterocyclylalkylsulfonyl or dialkylsulfamoyl; wherein alkyl, cycloalkyl and alyenyl can carry up to 6 carbon atoms alone or in compositions and can carry up to 6 ring members heterocyclically, alone, or in compositions and the groups R2and R3can be substituted; and to acid addition salts of compounds. The invention also relates to a method for producing the above 5-benzyl-2,4-diaminopyrimidines, to the intermediate. products that are produced, to corresponding medicaments and to the use of 5-benzyl-2,4-diaminopyrimidines as medicinal preparations. The products have antibiotic properties and are useful for combating or preventing infectious diseases.